Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (7)
Type
Type
Guidance (392)
NICE advice (1)
Quality standard (11)
Guidance programme
Guidance programme
Clinical guidelines (29)
Diagnostics guidance (7)
Health technology evaluations (17)
Highly specialised technologies guidance (10)
Interventional procedures guidance (21)
Medical technologies guidance (13)
NICE guidelines (32)
Public health guidelines (1)
Technology appraisal guidance (303)
Advice programme
Advice programme
Medtech innovation briefings (1)
Apply filters
Showing 351 to 400 of 404
Sort by
Title
Date
Apply sorting
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Targeted Muscle Reinnervation for refractory pain after limb amputation
Interventional procedures guidance
20 June 2025
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]
Technology appraisal guidance
11 December 2024
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401
Technology appraisal guidance
TBC
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]
Technology appraisal guidance
TBC
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]
Technology appraisal guidance
TBC
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]
Technology appraisal guidance
16 July 2025
Teprotumumab for treating thyroid eye disease [ID6432]
Technology appraisal guidance
20 August 2025
Third molars (impacted) - prophylactic removal [ID898]
Technology appraisal guidance
TBC
Tirzepatide for managing overweight and obesity [ID6179]
Technology appraisal guidance
14 January 2025
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy [ID4070]
Technology appraisal guidance
TBC
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]
Technology appraisal guidance
TBC
Tobacco: preventing uptake, promoting quitting and treating dependence - Cytisine for smoking cessation
NICE guideline
4 February 2025
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]
Highly specialised technology
TBC
Topical antimicrobial dressings for infected leg ulcers in people aged 16 and over: Late stage assessment
Health technology evaluation
22 May 2025
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]
Technology appraisal guidance
TBC
Total hip arthroplasty using the superpath approach for osteoarthritis
Interventional procedures guidance
TBC
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
Technology appraisal guidance
TBC
Transcatheter aortic valve implantation for native aortic valve regurgitation
Interventional procedures guidance
11 June 2025
Transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis: Late stage assessment
Health technology evaluation
8 January 2025
Transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia
Interventional procedures guidance
8 January 2025
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]
Technology appraisal guidance
10 September 2025
Treatments for non-small-cell lung cancer [ID6234]
Technology appraisal guidance
TBC
Triheptanoin for treating long-chain fatty acid oxidation disorders ID3891
Technology appraisal guidance
TBC
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]
Technology appraisal guidance
TBC
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]
Technology appraisal guidance
TBC
Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer [ID4061]
Technology appraisal guidance
TBC
Type 2 diabetes in adults: management (medicines update)
NICE guideline
19 June 2025
Ublituximab for treating relapsing multiple sclerosis [ID6350]
Technology appraisal guidance
TBC
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]
Technology appraisal guidance
TBC
Urinary Tract Infection (recurrent): antimicrobial prescribing
NICE guideline
12 December 2024
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]
Technology appraisal guidance
8 January 2025
Vamorolone for treating Duchenne muscular dystrophy [ID4024]
Technology appraisal guidance
TBC
Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over ID6372
Technology appraisal guidance
TBC
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]
Technology appraisal guidance
TBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]
Technology appraisal guidance
TBC
Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]
Technology appraisal guidance
TBC
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable [ID6291]
Technology appraisal guidance
TBC
Venglustat for treating gangliosidoses in people 2 years and over ID 6358
Technology appraisal guidance
TBC
Venoarterial extracorporeal membrane oxygenation (VA ECMO) for acute heart failure in adults
Interventional procedures guidance
6 August 2025
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]
Technology appraisal guidance
TBC
Violence and Aggression: short-term management in mental health, health and community settings
NICE guideline
TBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]
Technology appraisal guidance
TBC
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]
Technology appraisal guidance
10 September 2025
VTS-270 for treating Niemann-Pick type C1 [ID1267]
Highly specialised technology
TBC
Vutrisiran for treating transthyretin-related amyloidosis with cardiomyopathy [ID6470]
Technology appraisal guidance
TBC
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]
Technology appraisal guidance
22 November 2017
Women's and reproductive health guidelines
NICE guideline
TBC
Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]
Technology appraisal guidance
TBC
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]
Technology appraisal guidance
20 August 2025
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]
Technology appraisal guidance
TBC
Previous page
1
…
6
7
Current page
8
9
Page
8
of
9
Next page
Results per page
10
25
50
All
Back to top